Navigation Links
Icahn Asks Amylin to Allow Discussions With Eastbourne
Date:4/23/2009

NEW YORK, April 23 /PRNewswire/ -- Carl Icahn announced today that he had sent the following letter to James Wilson, Lead Independent Director of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN).

                                        April 23, 2009

    Mr. James Wilson
    Lead Independent Director
    Amylin Pharmaceuticals, Inc.
    9360 Towne Centre Drive
    San Diego, CA  92121

    Dear Jim:

    If you are really serious about settling what you consider a debilitating
    proxy contest, I believe it is mandatory for you to take the necessary
    action to allow Eastbourne and myself to talk without the threat of your
    poison pill and Section 203 preventing these discussions.  It is almost
    absurd that I and Eastbourne, separately, have had to ask you a number of
    times during last week and the week before to get permission to have these
    talks.  As I have said, even in a dictatorship parties that disagree with
    the ruling regime are allowed to talk to each other.  But not at Amylin.

    I sincerely believe that as a result of these discussions and subsequent
    discussions among the three of us, there will be enough common ground to
    resolve the matter.  What exactly are you afraid of?  The alternative is
    for the Company and its stockholders to continue to be distracted because
    of the inexplicable intransigence of the current Board which continues to
    evidence itself in so many ways, e.g. the poison pill, the poison puts,
    and the failure to heed the views of your co-founder, Howard E. Greene,
    Jr., regarding Joseph Cook's board seat.

    I look forward to your prompt response.

                                        Sincerely,

                                        Carl Icahn

SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY CARL C. ICAHN, DR. ALEXANDER J. DENNER, DR. THOMAS F. DEUEL, MR. JULES HAIMOVITZ, DR. PETER LIEBERT, DR. DAVID SIDRANSKY, MR. MAYU SRIS, MR. JEFFREY MECKLER, DR. ERIC ENDE, ICAHN Partners LP, Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Enterprises G.P. Inc., Icahn Enterprises Holdings L.P., IPH GP LLC, Icahn Capital L.P., Icahn Onshore LP, Icahn Offshore LP, Beckton Corp., AND CERTAIN OF THEIR RESPECTIVE AFFILIATES FROM THE STOCKHOLDERS OF AMYLIN PHARMACEUTICALS, INC, FOR USE AT ITS ANNUAL MEETING WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING TO THE PARTICIPANTS IN ANY SUCH PROXY SOLICITATION. WHEN COMPLETED, A DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY WILL BE AVAILABLE TO STOCKHOLDERS OF AMYLIN PHARMACEUTICALS, INC. FROM THE PARTICIPANTS AT NO CHARGE AND WILL ALSO BE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT HTTP://WWW.SEC.GOV.

INFORMATION RELATING TO THE PARTICIPANTS IN THIS PROXY SOLICITATION IS CONTAINED IN SCHEDULE 14A FILED BY THE PARTICIPANTS WITH THE SECURITIES AND EXCHANGE COMMISSION, WHICH DOCUMENTS ARE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT HTTP://WWW.SEC.GOV.


'/>"/>
SOURCE Carl Icahn
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Icahn Responds to Cornelius
2. Icahn Confirms Intention to Nominate Three Directors at Biogen
3. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
4. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
5. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
6. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
7. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... and scientists from around the world, is pleased to announce the 2nd annual ... 23, 2017. This premier, online-only conference focused on the development and advancements in ...
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... productivity traits and nutritional products, today announced their collaboration to achieve ... China to the United States ... ...
(Date:2/22/2017)... Zurich, Switzerland (PRWEB) , ... February 22, 2017 ... ... Ltd ., announced the addition of Tom Perkins as European director. Operating from ... consulting experience to Pennside. , Perkins joins Pennside after more than a ...
(Date:2/21/2017)... , Feb. 21, 2017 Synthetic Biologics, Inc. ... to preserve the microbiome to protect and restore the health of ... year ended December 31, 2016 on Thursday, March 2, 2017, and ... EST. The dial-in information for the call is as follows: ... ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/6/2017)... -- According to Acuity Market Intelligence, ongoing concerns ... continue to embrace biometric and digital identification based ... Control (ABC) eGates and 1436 Automated Passport Control ... ports of entry across the globe. Deployments increased ... CAGR of 37%. APC Kiosks reached 75% growth ...
Breaking Biology News(10 mins):